Details

Autor(en) / Beteiligte

• F. Linzee Mabrey
• Hui Nian
• Chang Yu
• Elizabeth M. Barnes
• Uma Malhotra
• Carmen Mikacenic
• Julia Goldstein
• D. Shane O'Mahony
• Julia Garcia-Diaz
• Patricia Finn
• Kirk Voelker
• Eric D. Morrell
• Wesley H. Self
• Patrice M. Becker
• Thomas R. Martin
• Mark M. Wurfel

Titel

Phase 2, randomized, double-blind, placebo-controlled multi-center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumoniaResearch in context

Ist Teil von

• EBioMedicine, 2023-07, Vol.93, p.104667

Ort / Verlag

Elsevier

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Background: Severe COVID-19 is associated with innate immunopathology, and CD14, a proximal activator of innate immunity, has been suggested as a potential therapeutic target. Methods: We conducted the COVID-19 anti-CD14 Treatment Trial (CaTT), a Phase II randomized, double-blind, placebo-controlled trial at 5 US-sites between April 12, 2021 and November 30, 2021 (NCT04391309). Hospitalized adults with COVID-19 requiring supplemental oxygen (<30 LPM) were randomized 1:1 to receive 4 daily doses of intravenous IC14, an anti-CD14 monoclonal antibody, or placebo. All participants received remdesivir. The primary outcome was time-to-resolution of illness, defined as improvement on the 8-point NIH-Ordinal COVID-19 Scale to category ≤3. Secondary endpoints were safety and exploratory endpoints were pro-inflammatory and antiviral mediators in serum on days 0–5 & 7. The trial was stopped after 40 patients were randomized and treated due to slow enrollment. Findings: 40 participants were randomized and treated with IC14 (n = 20) or placebo (n = 20). The median time-to-recovery was 6 days (95% CI, 5–11) in the IC14 group vs. 5 days (95% CI, 4–10) in the Placebo group (recovery rate ratio: 0.77 (95% CI, 0.40, 1.48) (log-rank p = 0.435). The number of adverse events was similar in each group, and no IC14-attributable secondary infections occurred. In repeated-measures mixed-effects analyses, IC14 treatment increased serum sCD14 concentrations, an expected pharmacodynamic effect. Pre-planned, exploratory analyses suggested that IC14 treatment decreased the trajectories of circulating MIP-1β and TNF-α. Interpretation: IC14 treatment did not improve time-to-resolution of illness in hypoxemic patients with COVID-19 in this small trial. Results of exploratory analyses suggested IC14 had biologic effects that warrant future clinical investigation. Funding: National Institute of Allergy and Infectious Diseases.